8-K: Rapid Micro Biosystems Reports Record 2025 Revenue, Secures Key Orders

Rapid Micro Biosystems announced record fourth quarter and full year 2025 financial results, alongside significant multi-system orders from Amgen and Samsung Biologics, and provided 2026 guidance.

Summary

• Rapid Micro Biosystems reported record total revenue of $11.3 million for the fourth quarter of 2025, a 37% increase compared to Q4 2024.
• Full year 2025 total revenue reached $33.6 million, representing 20% growth over 2024.
• The company placed 16 Growth Direct systems in Q4 2025 and 28 systems for the full year 2025, bringing cumulative placements to 190 and validated systems to 155 globally.
• Product revenue increased by 78% to $9.3 million in Q4 2025 and by 25% to $23.4 million for the full year 2025.
• Recurring revenue grew 10% to $4.6 million in Q4 2025 and 15% to $17.8 million for the full year 2025.
• GAAP gross margin percentage was negative 3% in Q4 2025 and 3% for the full year 2025, with non-GAAP adjusted gross margin at 7% and 6% respectively, excluding inventory write-offs.
• Net loss for Q4 2025 was $12.5 million ($0.28 per share) and $47.1 million ($1.05 per share) for the full year 2025.
• Cash, cash equivalents, short-term investments, and restricted cash totaled approximately $39.0 million as of December 31, 2025, with $25.0 million of unused debt facility capacity.
• The company secured a record multi-system order from Amgen in Q4 2025 and a meaningful multi-system order from Samsung Biologics in Q1 2026.
• For the full year 2026, the company expects total revenue between $37.0 million and $41.0 million, 30 to 38 Growth Direct system placements, and a gross margin percentage of approximately 20%.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by strong top-line revenue growth and significant customer wins, which indicate increasing market penetration and validation of the Growth Direct platform. While net losses persist, the projected improvement in gross margins for 2026 suggests a path towards better profitability.

Positives

• Achieved record total revenue of $11.3 million in Q4 2025, representing 37% year-over-year growth.
• Delivered 20% year-over-year total revenue growth for the full year 2025, reaching $33.6 million.
• Secured a record multi-system order from Amgen in Q4 2025, expanding global Growth Direct system rollout.
• Received a meaningful follow-on multi-system order from Samsung Biologics in Q1 2026, deepening the partnership and expanding platform deployment.
• Product revenue increased significantly by 78% in Q4 2025 and 25% for the full year 2025.
• Recurring revenue showed consistent growth, up 10% in Q4 2025 and 15% for the full year 2025.
• Full year 2025 GAAP gross margin percentage improved to 3% from 0% in 2024.
• Net loss per share attributable to common shareholders improved slightly for the full year 2025 to $1.05 from $1.08 in 2024.
• The company ended 2025 with approximately $39.0 million in cash, cash equivalents, short-term investments, and restricted cash, and $25.0 million in unused debt facility capacity.

Negatives

• Reported a net loss of $12.5 million in Q4 2025, an increase from $9.7 million in Q4 2024.
• Full year 2025 net loss remained substantial at $47.1 million, comparable to $46.9 million in 2024.
• GAAP gross margin percentage was negative 3% in Q4 2025, a decrease from positive 12% in Q4 2024.
• Service revenue decreased by 34% to $2.0 million in Q4 2025 compared to Q4 2024, attributed to the volume of validation activities.
• Total operating expenses increased by 6% to $11.9 million in Q4 2025 compared to Q4 2024.

Risks

• Significant losses since inception.
• Ability to meet publicly announced guidance and other expectations about business and operations.
• Effectiveness of sales and marketing efforts.
• Ability to sell and place products with customers.
• Ability to develop new products and adapt to technological change.
• Ability to establish and maintain its position as a leading provider of automated microbial quality control testing.
• Competition within the industry.
• Ability to maintain manufacturing operations.
• Efforts to improve gross margins for products.
• Ability to maintain and grow relationships with collaborators, including MilliporeSigma.
• Ability to manage collaboration with MilliporeSigma and realize intended benefits of the distribution and collaboration agreement.
• Ability to negotiate and enter into future collaboration opportunities with MilliporeSigma and realize intended benefits.
• Risks related to third-parties.
• Ability to retain key management and other employees.
• Risks related to regulatory and intellectual property matters.
• Risks related to supply chain disruptions and the impact of inflation.
• Impact of macroeconomic volatility on business and operations.

Future Outlook

For the full year 2026, Rapid Micro Biosystems expects total revenue in the range of $37.0 million to $41.0 million, including 30 to 38 Growth Direct system placements, and anticipates a gross margin percentage of approximately 20%.

Management Comments

• Robert Spignesi, President and CEO, stated, "We closed 2025 with significant momentum, delivering 20% year-over-year revenue growth."
• Spignesi highlighted, "Our performance was highlighted by key commercial wins, including a record multi-system order from Amgen in the fourth quarter."
• Spignesi noted, "This trajectory has continued into 2026, underscored by a meaningful multi-system order from Samsung Biologics in the first quarter."
• Spignesi emphasized, "These milestones demonstrate the accelerating global adoption of the Growth Direct platform as our customers standardize on our technology across their manufacturing networks."
• Regarding Samsung Biologics, Spignesi commented, "Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) and were pleased to strengthen our partnership with this new multi-system order."
• Spignesi added, "The Growth Direct platform enhances that foundation by delivering faster time to results, greater accuracy, and stronger data integrity. We look forward to supporting Samsung as it continues scaling its next-generation manufacturing operations."

Industry Context

StockSavvy.ai notes that Rapid Micro Biosystems' strong revenue growth and significant multi-system orders from industry leaders like Amgen and Samsung Biologics underscore the increasing demand for automation and digitalization in microbial quality control within the pharmaceutical and life sciences manufacturing sectors. The adoption of the Growth Direct platform by a major Contract Development and Manufacturing Organization (CDMO) like Samsung Biologics highlights a broader industry trend towards integrating advanced automation for improved efficiency, data integrity, and faster product release in the production of biologics, vaccines, and cell and gene therapies.

Comparison to Industry Standards

• No specific industry benchmarks or comparable companies, projects, or results were provided in the filing for direct comparison.

Stakeholder Impact

• Shareholders: Potential positive impact from strong revenue growth, significant customer wins, and positive 2026 guidance, but tempered by continued net losses.
• Customers (Amgen, Samsung Biologics): Enhanced operational efficiency, faster results, greater accuracy, and stronger data integrity through expanded deployment of the Growth Direct platform.
• Employees: Continued growth and strategic initiatives may lead to stability and potential expansion opportunities.
• Creditors: The company maintains $25.0 million in unused debt facility capacity, indicating liquidity and access to capital.

Next Steps

• Host a conference call on March 12, 2026, at 8:30 a.m. EST to discuss financial results.
• Continue to advance strategic priorities of accelerating Growth Direct system placements.
• Focus on expanding gross margin.
• Deliver new product innovation.
• Prudently manage cash.
• Amgen will sponsor North American Growth Direct Day in the second quarter 2026.

Key Dates

Recommendation

Rapid Micro Biosystems demonstrates strong commercial momentum with record revenue growth and significant multi-system orders from industry leaders like Amgen and Samsung Biologics, validating the market demand for its Growth Direct platform. While the company continues to report net losses, the projected 2026 guidance for increased revenue and a substantial improvement in gross margins to 20% indicates a positive trajectory towards profitability. For growth-oriented investors, the accelerating global adoption and strategic customer wins present a compelling long-term opportunity, despite current bottom-line challenges.

Keywords

Rapid Micro Biosystems, RPID, Growth Direct, automated microbiology, quality control, life sciences technology, pharmaceutical manufacturing, Amgen, Samsung Biologics, financial results, revenue, gross margin, net loss, 8-K